Chronic kidney disease (CKD) reflects progressive nephron loss and functional decline, stemming from diverse primary insults (diabetes, hypertension, glomerulonephritis, polycystic kidney disease).
Chronic kidney disease (CKD) reflects progressive nephron loss and functional decline, stemming from diverse primary insults (diabetes, hypertension, glomerulonephritis, polycystic kidney disease). Placental mesenchymal stem cells and their exosomes demonstrate anti-inflammatory and pro-regenerative properties relevant to CKD pathophysiology: they suppress macrophage infiltration into damaged glomeruli, inhibit fibrotic signalling pathways (TGF-β, SMAD2/3), and release growth factors that stabilise endothelial integrity. Eighty-eight registered trials and nine actively recruiting sites explore MSC infusion alongside conventional renin-angiotensin blockade and immunosuppression, particularly in early-to-intermediate stage disease where residual filtration capacity remains.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €15,000–€30,000 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Exosomes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 88 · 9 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Trial databases document glomerular filtration rate (GFR) trajectories in CKD cohorts receiving placental or umbilical-cord MSCs. Representative phase II studies report GFR decline stabilisation or modest improvement (mean +3–8 mL/min/1.73m² over 12 months) in 45–60% of participants, versus continued decline in placebo arms. Proteinuria reduction (24-hour urine protein <50% baseline) occurs in 35–50% within 6 months. Histological fibrosis progression slows in kidney biopsy samples from responders. These outcomes remain investigational; no large pivotal trial has yet shaped clinical guidelines.
Depending on assessment, a Chronic Kidney Disease protocol may draw on:
CKD protocols in Sofia and other Eastern European centres are priced €5,000–8,000 for complete treatment courses, typically involving 2–3 intravenous MSC infusions spaced 4–8 weeks apart, plus baseline and surveillance imaging (ultrasound, MRI), laboratory panels (glomerular filtration, proteinuria, immune markers), and nephrology consultation. Advanced disease stages (CKD 4–5, requiring dialysis transition planning) may incur additional costs for co-interventions or higher cell doses.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Chronic Kidney Disease cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Chronic Kidney Disease.
Full Chronic Kidney Disease FAQ → · Chronic Kidney Disease cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita